Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLSI 
Greenwich Lifesciences Inc (GLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: GLSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $45
1 Year Target Price $45
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.66% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 121.92M USD | Price to earnings Ratio - | 1Y Target Price 45 |
Price to earnings Ratio - | 1Y Target Price 45 | ||
Volume (30-day avg) 1 | Beta 2.91 | 52 Weeks Range 7.78 - 14.47 | Updated Date 12/5/2025 |
52 Weeks Range 7.78 - 14.47 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Earnings Date
Report Date 2025-11-10 | When - | Estimate -0.23 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -254.19% | Return on Equity (TTM) -543.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 112709694 | Price to Sales(TTM) - |
Enterprise Value 112709694 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -21.23 | Shares Outstanding 13854539 | Shares Floating 6581183 |
Shares Outstanding 13854539 | Shares Floating 6581183 | ||
Percent Insiders 50.59 | Percent Institutions 9.52 |
Upturn AI SWOT
Greenwich Lifesciences Inc
Company Overview
History and Background
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences. Founded in 2006, it has primarily focused on clinical trials and research for GP2.
Core Business Areas
- GP2 Immunotherapy Development: Greenwich LifeSciences' primary focus is the development and commercialization of GP2, a HER2/neu peptide-based immunotherapy for breast cancer prevention. This involves clinical trials, regulatory submissions, and potential manufacturing and distribution.
Leadership and Structure
Snehal Patel is the CEO of Greenwich LifeSciences. The company has a typical organizational structure for a clinical-stage biotech, focusing on research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- GP2: GP2 is Greenwich LifeSciences' sole product candidate. It is designed to prevent recurrence in HER2/neu positive breast cancer patients who have undergone prior treatment. Market share is currently 0 as GP2 is not yet approved. Competitors include companies developing HER2-targeted therapies and preventive vaccines, such as Roche (Herceptin), and AstraZeneca (Enhertu).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The oncology segment, particularly breast cancer therapeutics, is a significant area of focus. The current breast cancer treatment market is large and diverse, including chemotherapy, surgery, radiation, and targeted therapies.
Positioning
Greenwich LifeSciences is positioned as a company developing a novel immunotherapy for breast cancer prevention, targeting a specific patient population. Their competitive advantage relies on the potential efficacy and safety profile of GP2 compared to existing treatments.
Total Addressable Market (TAM)
The TAM for breast cancer recurrence prevention is substantial, estimated to be in the billions of dollars. Greenwich LifeSciences is positioned to capture a portion of this TAM if GP2 is approved and successfully commercialized. They are currently in phase III clinical trials.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Targeted treatment for HER2/neu positive patients
- Potential for long-term recurrence prevention
- Experienced management team
Weaknesses
- Single product pipeline
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- No approved products generating revenue
Opportunities
- Successful completion of Phase III clinical trials
- Regulatory approval from FDA and other agencies
- Partnerships with larger pharmaceutical companies
- Expansion of GP2 to other HER2-expressing cancers
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from existing and emerging therapies
- Patent challenges
- Funding constraints
Competitors and Market Share
Key Competitors
- ROCHE (ROG.SW)
- ASTRAZENECA (AZN)
- PFIZER (PFE)
Competitive Landscape
Greenwich LifeSciences faces competition from established pharmaceutical companies with broader pipelines and greater resources. Its advantage lies in the potential of GP2 as a targeted immunotherapy for breast cancer recurrence prevention, if the data is successful.
Growth Trajectory and Initiatives
Historical Growth: Greenwich LifeSciences' historical growth is limited, as it is a clinical-stage company focused on drug development.
Future Projections: Future growth is contingent on the successful development and commercialization of GP2. Analyst estimates vary widely, reflecting the inherent uncertainty in biotech investments.
Recent Initiatives: The company's recent initiatives include enrolling patients in the Phase III clinical trial of GP2.
Summary
Greenwich Lifesciences is a high-risk, high-reward clinical-stage biopharmaceutical company focused on a single product. Its success hinges on the Phase III clinical trial results for GP2. The company has limited financial resources, and faces competition from larger pharmaceutical players. Successful trial outcomes and potential partnerships are crucial for future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Investor presentations
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Greenwich Lifesciences Inc
Exchange NASDAQ | Headquaters Stafford, TX, United States | ||
IPO Launch date 2020-09-25 | CEO, CFO & Director Mr. Snehal S. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.